Aim: The aim of this study was to examine the role of adenosine A 1 receptors in the harmaline-induced tremor in rats using 5′-chloro-5′-deoxy-(±)-ENBA (5′Cl5′d-(±)-ENBA), a brain-penetrant, potent, and selective adenosine A 1 receptor agonist.
| INTRODUCTION
Harmaline (a β-carboline derivative) is a natural agent of plant origin, which induces tremor in humans 1 and is commonly used to model essential tremor (ET) in animals. 2 Similar to ET, 3 the harmalineinduced tremor is postural and kinetic, and its peak frequency in rats is 10-12 Hz. 2, [4] [5] [6] [7] [8] [9] It has been suggested that the harmaline-induced tremor is related to rhythmic firing of inferior olive neurons, 2,10 activation of the olivo-cerebellar glutamatergic climbing fibers, 2 elevation of glutamate release in the cerebellum, 11, 12 and an increase in complex spike discharges of Purkinje cells (PCs) of the cerebellar cortex. 10 Moreover, harmaline induces oscillations in deep cerebellar nuclei, medullary reticular formation, and spinal cord 10,13,14 and activates c-Fos expression in the olivo-cerebellar system and in the basal ganglia. 11, 15, 16 Besides phenomenological similarities between ET and the harmaline-induced tremor, their pharmacological treatments are also analogical. 3, 6, 8, 9 Moreover, a recent study has shown that, similar to its beneficial effect in ET, 17 high-frequency stimulation of the ventrolateral thalamic nucleus in mice (a region receiving glutamatergic projections from deep cerebellar nuclei 18, 19 ) reduced the harmaline-induced tremor. 20 The latter result emphasizes importance of the cerebellothalamic connectivity for both kinds of tremor.
Adenosine, a neuromodulatory nucleoside, is involved in a wide variety of physiological and pathological processes, and its G protein-coupled receptors (A 1 , A 2A , A 2B , and A 3 ) are targets for therapeutic intervention in several central and systemic disorders. 21 With regard to tremor therapy, A 2A but not A 1 receptor antagonists, such as DPCPX at doses which showed no in vivo occupancy of A 2A receptors, reduced tremulous jaw movements (a model of parkinsonian tremor) induced by cholinolytics or dopamine antagonists in rodents 22, 23 and alleviated the resting tremor in parkinsonian patients. 24 On the other hand, an intrathalamic infusion of an A 1 receptor agonist decreased the harmaline-induced tremor in mice, and A 1 receptors have been suggested to contribute to the therapeutic effect of the high-frequency stimulation in this model.
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The aim of this study was to examine the role of adenosine A 1 receptors in the harmaline-induced model of ET. To this aim, we used 5′-chloro-5′-deoxy-(±)-ENBA (5′Cl5′d-(±)-ENBA), a brain-penetrant, potent, and selective adenosine A 1 receptor agonist; the affinity of which for human A 1 receptors (Ki=0.51 nmol/L) has been reported to be 2500-5300 times higher than for A 2A , A 2B , or A 3 receptors. [25] [26] [27] Systemic injection of 5′Cl5′d-(±)-ENBA induced antinociception in the formalin model, 25 reduced neuropathic pain, 26 reduced locomotor activity and L-DOPA-induced dyskinesia 27 in mice, as well as influenced microglia physiology. 28 In contrast to other A 1 receptor agonists, peripheral side effects of 5′Cl5′d-(±)-ENBA were reported to be limited because at a dose of 0.5 mg/kg ip, it did not affect heart rate or systolic blood pressure in mice.
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In order to search for brain targets for potential tremorolytic effect of 5′Cl5′d-(±)-ENBA, we analyzed the zif-268 mRNA expression in different brain structures. Zif-268, similar to c-fos, belongs to the class of inducible immediate early genes (IEGs) that encode regulatory transcription factors and that have been implicated in various processes, including cell growth, differentiation, and apoptosis. 29 The zif-268 mRNA and protein are constitutively expressed in several rat brain structures 29, 30 and can be rapidly induced by a variety of physiological and pharmacological stimuli, including neurotransmitters (eg, glutamate), growth factors, seizures, ischemia, or cellular stress.
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Therefore, it represents a sensitive neurochemical marker useful in the evaluation of neuronal responses.
| METHODS

| Animals
The experiments were carried out according to the EU Directive 2010/63/EU for animal experiments and were approved by the local ethics committee at the Institute of Pharmacology. All efforts were made to minimize the number and suffering of animals used. Male
Wistar rats (240-350 g) were kept under a 12-h/12-h light/dark cycle (the light on from 7 AM to 7 pM) with free access to food and water. All experiments were carried out during the light period.
| Drugs
Harmaline hydrochloride dihydrate (Sigma-Aldrich, St Louis, MO, USA) was dissolved in redistilled water and administered as previously Immediately after harmaline injections, rats were placed in the FPA. To analyze the relationship between tremor and motility of rats, the distance in millimeter was further divided by 10 000 and the ratio AP2/distance was calculated.
| In situ hybridization of zif-268 mRNA
Quantitative in situ hybridization of zif-268 mRNA in rat brain structures was performed according to standard procedures used in our laboratory. 
| Statistics
Statistical analyses were carried out using the software Statistica v.10 (StatSoft Inc., Tulsa, OK, USA). In the behavioral experiments, ANOVA for repeated measures was used followed by LSD post hoc test for individual comparisons. In situ hybridization data were analyzed by one-way ANOVA and LSD post hoc test.
| RESULTS
| The harmaline-induced behaviors in rats
As reported previously, [6] [7] [8] harmaline induced generalized tremor of the whole body which started as early as a few minutes after its ad- Harmaline altered additionally locomotor activity of rats, measured by the total distance traveled. In agreement with our previous study, 7, 8 this drug reduced exploratory activity during the first 30 minutes after its injection but later (30-60 minutes) it increased motility of rats ( Figures 2 and 4 ). This hyperactivity was characterized by episodic slow locomotor movements, general agitation, and sniffing and was accompanied by ataxia, balance disturbances, and tremor.
| The effect of 5′Cl5′d-(±)-ENBA on the harmaline-induced tremor
5′Cl5′d-(±)-ENBA (0.01-0.5 mg/kg ip) dose dependently alleviated the tremor induced by harmaline (Figures 1 and 2 LSD post hoc test revealed that 5′Cl5′d-(±)-ENBA reversed the harmaline-induced increases in these parameters at doses of 0.05-0.5 mg/kg. In contrast, the lowest dose of 5′Cl5′d-(±)-ENBA (0.01 mg/ kg ip) was ineffective in this respect (Figures 1 and 2) .
None of the doses of 5′Cl5′d-(±)-ENBA influenced AP1 lowered by harmaline (Figures 1 and 2 ).
| The effect of 5′Cl5′d-(±)-ENBA on locomotor activity
5′Cl5′d-(±)-ENBA influenced locomotor activity of rats (treatment 
| DISCUSSION
The present study showed that 5′Cl5′d-(±)-ENBA, a potent and selective agonist of adenosine A 1 receptors administered systemically in rats, strongly and dose dependently reduced the tremor induced by harmaline. This effect was evidenced by reversal of the harmalineinduced increase in two tremor parameters: AP2 and the tremor index. Dependence of this tremorolytic effect of 5′Cl5′d-(±)-ENBA on adenosine A 1 receptors was proven by demonstration that it was abolished by DPCPX, a selective antagonist of these receptors.
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However, DPCPX administered alone did not influence the harmalineinduced tremor which indicated the lack of a modulating effect of endogenous adenosine on this disturbance. These results suggest that adenosine A 1 receptors may be a new target for ET therapy.
Our present study additionally revealed that, like other agonists of A 1 receptors 35 and its effects in mice, 25, 27 5′Cl5′d-(±)-ENBA in all tested doses decreased exploratory locomotor activity of rats measured as a distance traveled. Moreover, in higher doses it deepened the hypomotility and reversed hyperactivity induced by harmaline in the first (0-30 minutes) and second (30-60 minutes) periods after the latter agent injection, respectively. These effects of 5′Cl5′d-(±)-ENBA were abolished by DPCPX which supported the contribution of adenosine A 1 receptors.
It is well known that the tremor evoked by harmaline is action dependent.
2 Therefore, as 5′Cl5′d-(±)-ENBA induced parallel decreases in tremor and motility in the harmaline-treated rats, the former effect was likely to be secondary to its sedative properties. In the present study, however, we tested the hypothesis that these decreases were partly independent. To this aim, we calculated a ratio of AP2 (a parameter indicating the tremor intensity) to distance (a parameter reflecting motility). We have already applied the same method to propranolol (a drug well known to be efficient in treating essential tremor in hu-
) and found that this drug decreased AP2/distance ratio in the harmaline-treated animals which indicated its markedly stronger tremorolytic than sedative effect, 8 which was in line with its clinical efficiency. 3 In the present study, although 5′Cl5′d-(±)-ENBA at a low dose (0.05 mg/kg) did not change the AP2/distance ratio in the harmalinetreated rats, which reflected its parallel influence on tremor and motility, at higher doses (0.1-0.5 mg) this drug lowered it significantly.
Therefore, it seems that, at least at higher doses of 5′Cl5′d-(±)-ENBA, a certain independence of the mechanisms involved in its antitremor and antikinetic actions may be expected. antagonists. 4, 5, 9 In agreement with the above glutamatergic mechanisms, we found that harmaline evoked zif-268 mRNA expression, which is a marker of increased neuronal activity, 29, 30 in the inferior olive, cerebellar cortex, VA/VL nuclei of the thalamus, and the motor cortex. The increase in zif-268 expression in the inferior olive and cerebellar cortex was similar to that of c-Fos, reported earlier in these regions, 11, 15, 16 and was in line with the aforementioned activation of the olivocerebellar climbing fibers. 2, 11, 12 Similarly, it may be supposed that the harmaline-induced increase in zif-268 mRNA expression in the motor nuclei of the thalamus and the motor cortex resulted from activation of the cerebellotha- 
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The motor cortex in humans is a part of oscillatory network active in ET. 44 The present study showing the harmaline-induced increase in zif-268 expression in this structure and its reversal by 5′Cl5′d-(±)-ENBA may suggest that cortical adenosine A 1 receptors are involved in tremorolytic effect of the latter compound. This suggestion was further supported by a parallel antagonism, by DPCPX, of both inhibitory effects of 5′Cl5′d-(±)-ENBA on the harmaline-evoked tremor and cortical zif-268 expression. However, in contrast to ET, 44 harmaline has not been reported to induce oscillatory neuronal activity in the motor cortex in mice. 45 Therefore, a putative involvement of cortical A 1 receptors in the harmaline model may be related rather to its modulatory influence on the activity of the olivo-cerebellar system executed by a disynaptic cerebrocerebellar projection. 46, 47 Surprisingly, in contrast to the motor cortex, DPCPX did not antagonize the 5′Cl5′d-(±)-ENBA effect on the harmaline-induced increase in zif-268 mRNA expression in the inferior olive, cerebellum, and thalamus. As DPCPX has already been shown to inhibit, like an adenosine A 1 receptor agonist, the enhanced release of glutamate in rats, Several agonists of adenosine A 1 receptors have been developed as candidates for antiarrhythmic drugs because of their negative dromo-and chronotropic properties in humans. 55 These compounds slow down the heart rate and decrease systolic blood pressure in animals, 56, 57 which may be regarded as their side effects when used for other than cardiovascular indications. 5′Cl5′d-(±)-ENBA has been proposed to be superior to other A 1 receptor agonists because when administered in mice at the dose of 0.5 mg/kg ip, which inhibited mechanical and thermal allodynia, it neither induced cardiovascular effects nor disturbed motor coordination. 26 In the present study, 5′Cl5′d-(±)-ENBA reduced the harmaline-induced tremor of rats at doses ranging from 0.05 to 0.5 mg/kg. However, we noticed that the highest dose of this compound strongly depressed motor behavior of rats, which did not seem to result solely from its strong sedative effect.
Moreover, although we did not measure body temperature of rats, we noted by palpation a slight hypothermia induced by this dose which was in agreement with a recent study in mice. 58 Appearance of these disturbances of 5′Cl5′d-(±)-ENBA in rats which were not described (with the exception for the above hypothermia) in mice 26 may suggest species differences in metabolism of this drug. However, lower doses of 5′Cl5′d-(±)-ENBA were safer and induced only mild behavioral disturbances per se in rats which seems to be promising for future potential therapeutic use of adenosine A 1 receptor agonists as tremorolytic drugs.
Summing up, the present study suggests that adenosine A 1 receptors may be a potential therapeutic target for the treatment of ET.
However, as activation of these receptors induces several unwanted effects, namely sedation, cardiovascular depression, and hypothermia, clinical use of their agonists may be limited.
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